Pharmacological and therapeutic directions in ADHD: Specificity in the PFC. - Wikidata - awgldk - TriplyDB

Pharmacological and therapeutic directions in ADHD: Specificity in the PFC.

Pharmacological and therapeutic directions in ADHD: Specificity in the PFC.

http://www.wikidata.org/entity/Q37096227

about

Computational Psychiatry of ADHD: Neural Gain Impairments across Marrian Levels of Analysis Low dopamine function in attention deficit/hyperactivity disorder: should genotyping signify early diagnosis in children?The role of guanfacine as a therapeutic agent to address stress-related pathophysiology in cocaine-dependent individuals.Effect of atomoxetine on hyperactivity in an animal model of attention-deficit/hyperactivity disorder (ADHD).Dopaminergic and noradrenergic contributions to functionality in ADHD: the role of methylphenidate Hyperstimulation of striatal D2 receptors with sleep deprivation: Implications for cognitive impairment.Dopamine vs noradrenaline: inverted-U effects and ADHD theories.Sex-dependent changes in ADHD-like behaviors in juvenile rats following cortical dopamine depletion.Guanfacine extended-release for attention-deficit/hyperactivity disorder (ADHD).The role of alpha2-adrenergic agonists in attention-deficit/hyperactivity disorder.Methylphenidate transdermal system: clinical applications for attention-deficit/hyperactivity disorder.Non-medical use of methylphenidate: a review.The Effects of Guanfacine and Phenylephrine on a Spiking Neuron Model of Working Memory.Involvement of medial prefrontal cortex alpha-2 adrenoceptors on memory acquisition deficit induced by arachidonylcyclopropylamide, a cannabinoid CB1 receptor agonist, in rats; possible involvement of Ca2+ channels.Adrenoceptors in brain: cellular gene expression and effects on astrocytic metabolism and [Ca(2+)]i.Sensory gating deficit is associated with catechol-O-methyltransferase polymorphisms in bipolar disorder.Child psychopharmacology: Politics versus science

P2860

Q26770889-46AB42E0-E32F-4ADA-B5B9-AAD30E1E4FE3 Q27026214-472A2C0D-35FC-4D57-A4A3-582B80539680 Q33598487-97E0EF93-3395-4E33-8E7F-C345D75F7927 Q34278294-CDC145FB-B409-491D-AEAF-B1B7C4F7736C Q34991378-B2461984-BBEE-4C81-B039-1A958DB295A0 Q37271978-0DD04330-D26A-44EA-9E63-45359BCA4326 Q37372629-8355F336-58E7-4848-80ED-7C02B3915731 Q37587449-F65D76A8-9B16-4638-8321-5063BC8CD6D9 Q37787239-A71817DC-A554-462C-9419-7A2BB83CF7BD Q37791316-EC7655C7-838F-4F18-86DD-6C268D8769DC Q37960505-D32B2B9F-9757-4798-B68F-F2B9C606659D Q38448645-4835F9B2-D9C7-4AC8-BD77-16161F9BA37E Q39078231-8234492D-D381-4530-8728-BFE273673EF9 Q39674218-ADE38FCA-CC57-4619-BC0D-5FE6AE941872 Q42256211-8906C6A1-62A2-4F0A-BD24-E30D7435E9DF Q51461425-50C5723F-2039-4036-9D74-CBD0B3EC2DB9 Q56866353-355E6EC2-5F55-434C-BCC9-14B58B8B366A

P2860

Pharmacological and therapeutic directions in ADHD: Specificity in the PFC.

http://www.wikidata.org/entity/Q37096227

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 28 February 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Pharmacological and therapeutic directions in ADHD: Specificity in the PFC.

@en

Pharmacological and therapeutic directions in ADHD: Specificity in the PFC.

@nl

type

label

Pharmacological and therapeutic directions in ADHD: Specificity in the PFC.

@en

Pharmacological and therapeutic directions in ADHD: Specificity in the PFC.

@nl

prefLabel

Pharmacological and therapeutic directions in ADHD: Specificity in the PFC.

@en

Pharmacological and therapeutic directions in ADHD: Specificity in the PFC.

@nl

P1433

Q37096227-B5CCCBD8-BB58-4C1F-A686-2C691F253BE1

P1476

Q37096227-CDA66CF2-2DBA-4CC1-B7F2-83D9713819DE

P2093

Q37096227-02A11503-D719-4B41-B66D-0E0E524ED412

P2860

Q37096227-01550939-049B-42B9-9FDA-4C7476A77791

Q37096227-01C7D930-EFE5-4BC4-9DB4-C8C54CDDE2D7

Q37096227-067AC496-DA69-4B05-8598-FE2B6948EEB4

Q37096227-074B4D23-3918-4A82-B083-E0AFBF84CF99

Q37096227-089B5B1C-BC93-4F02-A9EA-DA116DD523BE

Q37096227-0BB25142-6342-4B8C-88FB-9E71A96195A0

Q37096227-0CA36672-D27F-4197-ADB5-9CC61B7A19B9

Q37096227-0DF8B764-E850-4AE7-B56A-8BEBE277CE2F

Q37096227-11158370-C630-4892-869F-441B1284C526

Q37096227-1138E956-C09C-4034-A8EE-BC948CF072C2

P2888

Q37096227-40F669FA-2DE9-45C9-B194-E721F1827940

P304

Q37096227-44FAF360-F9B6-4111-8866-5F3E9FB6F282

P31

Q37096227-C0643BD6-D134-4582-AFC8-F308AFDED320

P356

Q37096227-40C32E8F-3809-44D1-B13B-DA5C24B0E34C

P407

Q37096227-9F77F945-B2C0-4CC9-947A-DD87CBA266E6

P478

Q37096227-1EF3FE5A-9558-475E-8D21-64956F40030E

P577

Q37096227-9828105F-4984-4713-800B-AD44892D569F

P5875

Q37096227-7A153CC1-0620-4BD5-80AA-B9B819F2C77E

P6179

Q37096227-500D86BB-0D11-4FC2-9723-5224BE57D2CB

P698

Q37096227-79F3F03C-D07E-4AFE-B5EC-944B37628BB8

P921

Q37096227-947F1645-D214-45CB-B526-3507066DAB5A

P932

Q37096227-16285663-4117-4FE7-B56A-B6EE42862772

P356

P1433

Behavioral and Brain Functions

P1476

Pharmacological and therapeutic directions in ADHD: Specificity in the PFC.

@en

P2093

Florence Levy

http://www.w3.org/2001/XMLSchema#string

P2860

Methylphenidate improves prefrontal cortical cognitive function through alpha2 adrenoceptor and dopamine D1 receptor actions: Relevance to therapeutic effects in Attention Deficit Hyperactivity Disorder.

Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines

A dynamic developmental theory of attention-deficit/hyperactivity disorder (ADHD) predominantly hyperactive/impulsive and combined subtypes

Potentiation of NMDA receptor currents by dopamine D1 receptors in prefrontal cortex

Cellular basis of working memory

alpha2-Adrenergic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: emerging concepts from new data.

Increased dopamine turnover in the prefrontal cortex impairs spatial working memory performance in rats and monkeys.

Developing a neuronal model for the pathophysiology of schizophrenia based on the nature of electrophysiological actions of dopamine in the prefrontal cortex.

Impairment of social and moral behavior related to early damage in human prefrontal cortex.

Destruction and creation of spatial tuning by disinhibition: GABA(A) blockade of prefrontal cortical neurons engaged by working memory.

P2888

P304

12

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1744-9081-4-12

http://www.w3.org/2001/XMLSchema#string

P407

P478

4

http://www.w3.org/2001/XMLSchema#string

P577

2008-02-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5548841

http://www.w3.org/2001/XMLSchema#string

P6179

1000619320

http://www.w3.org/2001/XMLSchema#string

P698

18304369

http://www.w3.org/2001/XMLSchema#string

P921

P932

2289834

http://www.w3.org/2001/XMLSchema#string